ArticleCurrent microbiology2026
Evaluation of Antibacterial Properties of Nanosuspension of Secondary Metabolites from Streptomyces chrestomyceticus ADP4.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examines a nanosuspension of secondary metabolites (NSM) derived from Streptomyces chrestomyceticus strain ADP4, previously reported for its antifungal efficacy against Candida spp., and extends its evaluation to WHO-listed high-priority bacterial pathogens. The antibacterial potential of the NSM was assessed against Staphylococcus aureus ATCC 25,923, Enterococcus faecium ATCC 49,924, and Enterococcus faecalis ATCC 29,212. Transmission electron microscopy revealed the formation of uniformly dispersed, spherical nanoparticles with an average diameter of 14 ± 4.26 nm. Compared with the crude secondary metabolites (SMs), the NSM demonstrated noticeably enhanced antibacterial performance, reflected by increased zones of inhibition (10%, 16%, and 26%), significant reductions in minimum inhibitory concentrations (53%, 42%, and 71%), and improved minimum biofilm inhibitory concentrations (41%, 30%, and 70%) against S. aureus, E. faecium, and E. faecalis, respectively. The observed enhancement in antimicrobial and antibiofilm activity highlights the role of nano-formulation in improving the bioavailability and biological efficiency of microbial SMs. Also, the flow cytometric analysis of bacterial cells treated with SMs and NSM revealed an increase in membrane permeability in a dose- and time-dependent manner. These findings highlight the potential of actinobacteria-derived NSM as environmentally relevant and support its applicability in macromolecular and surface-associated biomedical applications, including antibiofilm coatings for medical devices, wound dressings, and infection-resistant biomaterials making NSM as a potential strategy for sustainable and microbe-driven innovation.
Indexed as
Identifiers
42547538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.